1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid (CAS 1640981‑19‑6) is a substituted benzimidazole derivative featuring a 6,5‑fused aromatic heterocyclic system. The molecule incorporates a benzyl group at the 1‑position, a 4‑hydroxy substituent, a 2‑methyl group, and a carboxylic acid at the 6‑position, molecular formula C₁₆H₁₄N₂O₃ and molecular weight 282.29 g/mol.
1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid is a key intermediate and impurity reference standard in the industrial synthesis of tegoprazan, a novel P‑CAB indicated for GERD and erosive oesophagitis. The benzimidazole core of 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid provides the essential heterocyclic framework for tegoprazan‘s pharmacological activity. In quality control contexts, 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid is officially designated as Tegoprazan Impurity 4, making it an indispensable analytical reference standard for impurity profiling, analytical method development, method validation, QC testing, and ANDA filings for generic tegoprazan manufacturers. The carboxylic acid group of 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid enables further derivatisation to amides, esters, and other functional groups, expanding its utility in medicinal chemistry and process development. Because of its dual role, 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid is available in multiple grades to suit both synthesis and analytical needs.
When your tegoprazan ANDA filing requires reliable impurity reference standards with full characterisation data, Cosperpharm delivers 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid with the analytical rigor and documentation depth that regulatory submissions demand.
Precision for impurity profiling. As Tegoprazan Impurity 4, this compound is a mandatory reference standard for analytical method validation. Our reference‑grade product includes comprehensive characterisation data—NMR, HPLC, and mass spectrometry—to support your regulatory submission.
Documentation that supports ANDA filings. Every reference‑grade shipment includes a COA with batch‑specific purity, chromatographic traceability, and characterisation data—structured for direct insertion into your method validation package. Stability summaries and custom quality agreements are available upon request.
Dual‑use intermediate and impurity standard. Supplied at multiple quality levels—as a synthetic intermediate and as Impurity 4 for QC testing.
Regulatory expertise. Our team understands the specific requirements for impurity reference standards in ANDA filings and can provide the documentation you need.
Product Advantages
Official tegoprazan impurity standard – Designated as Tegoprazan Impurity 4.
Comprehensive characterisation – Reference‑grade product includes NMR, HPLC, MS data.
Dual‑use – Serves as both intermediate and impurity standard.
Cosperpharm maintains rigorous QC for this compound. Each batch is tested by HPLC (≥97%), structural confirmation (NMR/MS), and residual solvent analysis. A COA with full characterisation accompanies every shipment. Full traceability is maintained.
Contact Us
Need 1‑Benzyl‑4‑hydroxy‑2‑methyl‑1H‑benzo[d]imidazole‑6‑carboxylic acid for your tegoprazan impurity profiling or ANDA filing? Cosperpharm is your trusted partner for impurity reference standards. Reach out today—our regulatory documentation and analytical expertise are ready to support your submission.
Hot Tags: 1-benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid, China, Manufacturer, Supplier, Factory
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.Privacy Policy